248 related articles for article (PubMed ID: 33904001)
21. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
[TBL] [Abstract][Full Text] [Related]
22. Preoperative transarterial chemoembolization for hepatocellular carcinoma.
Kishi Y; Saiura A; Yamamoto J; Koga R; Seki M; Morimura R; Yoshioka R; Kokudo N; Yamaguchi T
Hepatogastroenterology; 2012 Oct; 59(119):2295-9. PubMed ID: 23435144
[TBL] [Abstract][Full Text] [Related]
23. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
24. Role of surgical resection for multiple hepatocellular carcinomas.
Choi SH; Choi GH; Kim SU; Park JY; Joo DJ; Ju MK; Kim MS; Choi JS; Han KH; Kim SI
World J Gastroenterol; 2013 Jan; 19(3):366-74. PubMed ID: 23372359
[TBL] [Abstract][Full Text] [Related]
25. Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma.
Yuan P; Song J; Wang F; Zhu G; Chen B
Invest New Drugs; 2022 Oct; 40(5):1125-1132. PubMed ID: 35793038
[TBL] [Abstract][Full Text] [Related]
26. Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.
Qu WF; Ding ZB; Qu XD; Tang Z; Zhu GQ; Fu XT; Zhang ZH; Zhang X; Huang A; Tang M; Tian MX; Jiang XF; Huang R; Tao CY; Fang Y; Gao J; Wu XL; Zhou J; Fan J; Liu WR; Shi YH
BJS Open; 2022 Sep; 6(5):. PubMed ID: 36125345
[TBL] [Abstract][Full Text] [Related]
27. Long-term survival after surgical resection for huge hepatocellular carcinoma: comparison with transarterial chemoembolization after propensity score matching.
Min YW; Lee JH; Gwak GY; Paik YH; Lee JH; Rhee PL; Koh KC; Paik SW; Yoo BC; Choi MS
J Gastroenterol Hepatol; 2014 May; 29(5):1043-8. PubMed ID: 24863186
[TBL] [Abstract][Full Text] [Related]
28. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
Watanabe T; Koyama N
Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
[TBL] [Abstract][Full Text] [Related]
29. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment.
Yamashige D; Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Muraishi N; Kajiwara A; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
Oncology; 2021; 99(3):169-176. PubMed ID: 33207358
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of hepatic resection and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria].
Guo Z; Xiang B; Zhang J; Jiang J; Li L
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1526-9. PubMed ID: 25146737
[TBL] [Abstract][Full Text] [Related]
31. Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Zhu XD; Huang C; Shen YH; Xu B; Ge NL; Ji Y; Qu XD; Chen L; Chen Y; Li ML; Zhu JJ; Tang ZY; Zhou J; Fan J; Sun HC
Ann Surg Oncol; 2023 May; 30(5):2782-2790. PubMed ID: 36178565
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety.
Wei W; Jian PE; Li SH; Guo ZX; Zhang YF; Ling YH; Lin XJ; Xu L; Shi M; Zheng L; Chen MS; Guo RP
Cancer Commun (Lond); 2018 Oct; 38(1):61. PubMed ID: 30305149
[TBL] [Abstract][Full Text] [Related]
33. Hepatic Resection after Initial Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for the Treatment of Hepatocellular Carcinoma: A Meta-analysis of Observational Studies.
Tang YL; Qi XS; Guo XZ
Asian Pac J Cancer Prev; 2015; 16(17):7871-4. PubMed ID: 26625813
[TBL] [Abstract][Full Text] [Related]
34. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
35. Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
Huang YK; Yen CL; Shiu SI; Lee SW; Chang PY; Yeh HZ; Lee TY
PLoS One; 2017; 12(11):e0188999. PubMed ID: 29190692
[TBL] [Abstract][Full Text] [Related]
36. Hepatic resection alone versus in combination with pre- and post-operative transarterial chemoembolization for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
Qi X; Liu L; Wang D; Li H; Su C; Guo X
Oncotarget; 2015 Nov; 6(34):36838-59. PubMed ID: 26451613
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y
Liver Int; 2020 Apr; 40(4):968-976. PubMed ID: 32064740
[TBL] [Abstract][Full Text] [Related]
38. A prognostic model and treatment strategy for intrahepatic recurrence of hepatocellular carcinoma after curative resection.
Umeda Y; Matsuda H; Sadamori H; Matsukawa H; Yagi T; Fujiwara T
World J Surg; 2011 Jan; 35(1):170-7. PubMed ID: 20922387
[TBL] [Abstract][Full Text] [Related]
39. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma.
Kawamura Y; Kobayashi M; Shindoh J; Kobayashi Y; Okubo S; Tominaga L; Kajiwara A; Kasuya K; Iritani S; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kozuka T; Kumada H
Liver Cancer; 2020 Dec; 9(6):756-770. PubMed ID: 33442544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
